DermTech Presents Research Abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting and New Research Published in the Journal of Investigative Dermatology
DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced the presentation of two research abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting, taking place March 8th-12th in San Diego, California.
- DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced the presentation of two research abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting, taking place March 8th-12th in San Diego, California.
- “This real-world clinical study demonstrates that the DMT can help clinicians improve outcomes for cutaneous melanomas in patients of all skin types,” commented Dr. Skelsey.
- The research found that somatic mutations in healthy-appearing sun-exposed skin indicate an increased risk for skin cancer.
- Furthermore, these mutations capture skin cancer risk information that is not accounted for by other risk factors.